SICHUAN, China, July 17, 2012 /PRNewswire-Asia/ -- China Health Resource, Inc. (CHRI) announced today the successful development of a revolutionary TCM migraine medication called Toufeng Migraine tablet. The medication has demonstrated an effective rate of 96.5% in clinical observations. The new product was developed utilizing the company's Dahurian Angelica (DAR) as one it's key ingredients.
According to the company's forecast, the world's major pharmaceutical markets (USA, France, Germany, Italy, Spain, Britain and Japan) for anti-migraine drug sales will grow from $2.86 billion in 2002 to over $5.6 billion by 2013. Unlike Toufeng Migraine tables, most available medications are pain killers and many have serious side effects or carry a risk of dependency and addiction.
"Toufeng Migraine tablets have proven effective in our tests. It is naturally derived from our trademarked Sichuan DAR. This new product has a strong export market demand with a potential for immeasurable health benefits. We expect this to provide tremendous economic growth for CHRI," says Jiayin Wang, Chairman and CEO of CHRI.
The company is now moving forward with the approval process world-wide and is working to develop and expand commercialization through strategic partnerships.
The American Headache Foundation statistics show that one in every ten people in the United States suffers from migraine headaches, but more than half the patients fail to report it. According to international epidemiological surveys, the incidence of migraines world-wide is 8.4% to 28%. Data from the U.S. National Institute of Neurological Disorders and Obstruction shows that lost productivity by migraine patients in the United States has reached 157 million working days a year. In China, prevalence rate for migraine is 9.85% and the annual incidence rate is 7.97%. With China's population of 1.3 billion, this percentage translates to 103.6 million people. Migraine headaches have become a major international problem.
"The company is committed to the development and commercialization of effective, innovative and natural health solutions. We are very pleased with this new development of Toufeng tablets," adds Mr. Wang.
Press Contact:
Ms. Cynthia Bitting
Contact Tel. (USA) +1 314-442-0368
USA Rep for China Health Resource INC.
Email: info@chinahealthresource.com
www.chinahealthresource.com
China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of raw and pharmaceutical TCM products including Dahurian Angelica Root (DAR) and Rhizoma Gastrodiae and is only the provider of GAP quality DAR in the People's Republic of China under the registered Trademark Chuan Baizhi™. DAR, which is also known as "Bai Zhi" in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The Company's DAR-related products include the Bailing Capsule and Yishen Capsule, all of which are sold through regional distributors. The Company was founded in 2001.
Certain statements in this document regarding financial matters, other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.